Sodium-glucose co-transporter 2 inhibitors (SGLT-2i),the most recently developed oral hypoglycemic agents acted on renal proximal tubules,suppress glucose reabsorption and increase urinary glucose excretion.Besides their ability to lower plasma glucose,blood pressure,plasma uric acid concentration and the cardiovascular (CV) safety by decreasing the independent CV risk factors,the SGLT-2i offers the possibility of kidney protection.Simultaneous use of SGLT-2i and RAAS blockers are novel strategies to slow the progression of diabetic kidney disease (DKD).The present review was to review the mechanisms of potentially renoprotective benefits of SGLT-2i in patients with DKD.%钠-葡萄糖共转运蛋白2抑制剂(SGLT-2i)是一种新型的口服降糖药,可通过抑制肾脏近曲小管对葡萄糖重吸收,促进尿糖排泄进而降低血糖.该类药物除了能降血糖、降血压、改善血尿酸水平及减少心血管事件危险因素外,还具有潜在的肾脏保护作用.SGLT-2i联用肾素-血管紧张素-醛固酮系统(RAAS)阻断剂是一种延缓糖尿病肾病进展的新策略.本文就SGLT-2i作用机制及其肾脏保护作用做一综述.
展开▼
